Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cardiac Fibroblast Activation Detected by 68Ga-FAPI PET/MR is a Prognostic Indicator in Patients With Myocardial Infarction.

NCT04723953 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT04723953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04723953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cardiac Fibroblast Activation Detected by 68Ga-FAPI PET/MR is a Prognostic Indicator in Patients With Myocardial Infarction.
Lead sponsor
Ruijin Hospital
Phase
Not applicable
Overall status
Completed
Start date
August 26, 2020
Completion date
September 30, 2022
Enrollment
89 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myocardial remodeling after ami